Pharma’s Biggest Blind Spot: Why 99.9% of Chemical Space Was Never Explored | Dr. Olga Nissan, Ph.D. - Vice President of Business Development, Evogene

Episode notes

Send us Fan Mail Pharma has only explored a tiny fraction - less than one-tenth of one percent - of all possible drug-like molecules. So the question is: what happens when AI suddenly opens up the other 99.9%? Dr. Olga Nissan, Ph.D. is Vice President of Business Development at Evogene ( ) where she leads pharmaceutical partnerships for the company’s ChemPass AI generative chemistry platform - an advanced system designed to dramatically expand the searchable universe of drug-like molecules. With over 15 years of experience spanning biotech, pharma, and computational biology, Dr. Nissan operates at the intersection of science, strategy, and commercialization. Prior to Evogene, she was Co-Founder and CEO of Protica Bio, a precision oncology company focused on translating novel biological insights into therapeutic opportunities. Earlier in her career, she held scientific and operational roles at Teva Pharmaceutical Industries, as well as EcoPhage and BiomX, building expertise across microbiology, molecular biology, and translational R&D. Dr.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• Utilizing AI internally to iterate faster and empower smaller teams to upskill w/ Vivek Raghunathan #263The Engineering Leadership Podcast · on generative AI96 / 100
• AI Is Ready for Government. Is Government Ready?The So What from BCG · on generative AI84 / 100
• Season 4 Episode 8: Freedom To FailThe Longer Game · on generative AI79 / 100
• How CX Leaders Can Win With AI with Greg MeliaBusiness Transformation Pitch with The CX Goalkeeper · on generative AI77 / 100
• RBC's Kelly Bradley on Disclosure, Disruption, and Developing TalentHBS Managing the Future of Work · on generative AI77 / 100
• Determining when to leave to start your own company, making strategic bets, and selling to enterprise customers w/ Anhang Zhu @ TierZeroEngineering Founders · on generative AI76 / 100

• Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100
• The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera65 / 100
• How Female Biology Shapes Skin Disease Across a Lifetime | Dr. Doral Fredericks, PharmD, MBA - Vice President and Head of Global Medical Affairs and Outcomes Research, Organon56 / 100
• 55 Years Without a Diagnosis | Can AI Solve The Undiagnosed Condition Blind Spot? | Haresh Patel - Founder and CEO, Sanare Health AI70 / 100
• How Regenerative Medicine Is Reinventing Breast Reconstruction | Dr. Claudia Chavez-Munoz, MD, PhD - Chief Scientific Officer and Co-Founder - Conexeu Sciences